Generation of LTB4-BLT2-dependent reactive oxygen species (ROS) promotes anti-apoptotic, invasive, and metastatic phenotypes in cancer cells [30–33], suggesting that BLT2 antagonists might be candidates for therapeutic agents against cancer. The gene discussed is LTB4R2; the disease is cancer.